ID HC-04 AC CVCL_Z631 SY HC04; HCO4 DR ArrayExpress; E-MTAB-6919 DR BEI_Resources; MRA-975 DR cancercelllines; CVCL_Z631 DR PRIDE; PXD008613 DR Wikidata; Q54881462 RX Patent=US7015036; RX PubMed=16687667; RX PubMed=17590308; RX PubMed=22990793; RX PubMed=24532842; RX PubMed=30891005; CC Group: Malaria research cell line. CC Group: Patented cell line. CC Problematic cell line: Possibly contaminated. Indicated (PubMed=24532842) to have a near genetic identity with Hep-G2 cells. But they are functionally different from Hep-G2 cells since they support sporozoite invasion and liver stage exoerythrocytic development of Plasmodium falciparum and Plasmodium vivax. But STR profile from BEI Resources is identical to that of Hep-G2. Originally thought to originate from the spontaneous immortalization of a normal liver tissue of an hepatoma patient. CC Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3441. CC Population: Caucasian. CC Doubling time: ~24 hours (PubMed=17590308). CC Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line). CC Omics: Proteomics. CC Omics: Transcriptomics; RNAseq. CC Derived from site: In situ; Liver; UBERON=UBERON_0002107. ST Source(s): BEI_Resources=MRA-975 ST Amelogenin: X,Y ST CSF1PO: 10,11 ST D13S317: 9,13 ST D16S539: 12 ST D5S818: 11,12 ST D7S820: 10 ST TH01: 9 ST TPOX: 8,9 ST vWA: 17 DI NCIt; C3728; Hepatoblastoma DI ORDO; Orphanet_449; Hepatoblastoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) HI CVCL_0027 ! Hep-G2 SX Male AG 15Y CA Cancer cell line DT Created: 10-04-15; Last updated: 10-04-25; Version: 25 // RX Patent=US7015036; RA Prachumsri J., Yimamnuaychok N.; RT "Human liver cell line."; RL Patent number US7015036, 21-Mar-2006. // RX PubMed=16687667; DOI=10.4269/ajtmh.2006.74.708; RA Sattabongkot J., Yimamnuaychok N., Leelaudomlipi S., Rasameesoraj M., RA Jenwithisuk R., Coleman R.E., Udomsangpetch R., Cui L.-W., RA Brewer T.G.; RT "Establishment of a human hepatocyte line that supports in vitro RT development of the exo-erythrocytic stages of the malaria parasites RT Plasmodium falciparum and P. vivax."; RL Am. J. Trop. Med. Hyg. 74:708-715(2006). // RX PubMed=17590308; DOI=10.1016/j.tiv.2007.05.003; RA Lim P.L.K., Tan W.-Q., Latchoumycandane C., Mok W.C., Khoo Y.M., RA Lee H.S., Sattabongkot J., Beerheide W., Lim S.G., Tan T.M.C., RA Boelsterli U.A.; RT "Molecular and functional characterization of drug-metabolizing RT enzymes and transporter expression in the novel spontaneously RT immortalized human hepatocyte line HC-04."; RL Toxicol. In Vitro 21:1390-1401(2007). // RX PubMed=22990793; DOI=10.1007/978-1-62703-026-7_27; PMCID=PMC3951895; RA Sinnis P., De La Vega P., Coppi A., Krzych U., Mota M.M.; RT "Quantification of sporozoite invasion, migration, and development by RT microscopy and flow cytometry."; RL Methods Mol. Biol. 923:385-400(2013). // RX PubMed=24532842; DOI=10.1074/mcp.M113.035584; PMCID=PMC4014276; RA Tao D.-Y., King J.G., Tweedell R.E., Jost P.J., Boddey J.A., RA Dinglasan R.R.; RT "The acute transcriptomic and proteomic response of HC-04 hepatoma RT cells to hepatocyte growth factor and its implications for Plasmodium RT falciparum sporozoite invasion."; RL Mol. Cell. Proteomics 13:1153-1164(2014). // RX PubMed=30891005; DOI=10.3389/fmicb.2019.00127; PMCID=PMC6413710; RA Tweedell R.E., Tao D.-Y., Hamerly T., Robinson T.M., Larsen S., RA Gronning A.G.B., Norris A.M., King J.G., Law H.C.-H., Baumbach J., RA Bergmann-Leitner E.S., Dinglasan R.R.; RT "The selection of a hepatocyte cell line susceptible to Plasmodium RT falciparum sporozoite invasion that is associated with expression of RT glypican-3."; RL Front. Microbiol. 10:127.1-127.16(2019). //